ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

Sarah Cannon Research Institute at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Sarah Cannon Research Institute takes part in 16 sessions at ESMO 2026 in Madrid. Its work centres on drug development and treatment strategies across lung, prostate, breast and skin cancers. It covers targeted drugs and antibody-based treatments, including studies of therapies for metastatic prostate cancer and melanoma.

OrganizationESMO 2026 Attendance
CRO & services
Oncology research organization based in Nashville, Tennessee, running cancer clinical trials across a network of US community sites.
Poster
Fri Oct 23
15:15–16:00
Poster
Fri Oct 23
15:15–16:00
Phase 1 study of BHV-1530, a first-in-class FGFR3 ADC in advanced tumors
Friday Poster Display session 6
Satellite
Fri Oct 23
18:45–19:00
Persistent Unmet Need in mUM: Limitations of Current Approaches
Servier - Toward a New Paradigm in Metastatic Uveal Melanoma: From Biological Insight to Practical Treatment Strategies
Melanoma & skin cancers
Poster
Sat Oct 24
12:00–12:45
Darovasertib and crizotinib for HLA-A*02–positive metastatic uveal melanoma: Results from the phase 2 OptimUM-01 study
Saturday Poster Display session 4
Melanoma & skin cancersSarcoma, CNS, head & neck and rare cancers
Poster
Sat Oct 24
12:00–12:45
Efficacy, safety, and biomarker analysis of DB-1310 (HER3-targeted ADC) in pretreated HR+/HER2- breast cancer: Updated global phase 1/2a trial
Saturday Poster Display session 2
Breast cancerBiomarkers & precision oncology
Talk
Sat Oct 24
14:45–15:05
Drugging the undruggables: The next wave of targeted therapies
YO Lecture: What to expect from precision medicine in the next decade
Biomarkers & precision oncology
Talk
Sat Oct 24
16:45–17:00
Next generation therapies
Novel concepts for metastatic breast cancer: Looking to the future
Breast cancerBiomarkers & precision oncology
Abstract
Sun Oct 25
10:15–10:20
Abstract
Sun Oct 25
11:23–11:35
Invited Discussant LBA66, LBA67 and LBA68
Proffered paper 1: NSCLC, metastatic
Lung & thoracic cancers
Poster
Mon Oct 26
12:00–12:45
Poster
Mon Oct 26
12:00–12:45

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Sarah Cannon Research Institute

Tell us what you sell and we’ll find the people at Sarah Cannon Research Institute most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction